Scarica l'app Stockscreener
719.39
0.80%
-5.83
Dopo l'orario di chiusura:
723.00
3.61
+0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$725.22
Aprire:
$725.22
Volume 24 ore:
2.93M
Relative Volume:
0.73
Capitalizzazione di mercato:
$681.79B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
58.53
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
-0.77%
1M Prestazione:
-18.00%
6M Prestazione:
-8.73%
1 anno Prestazione:
-10.95%
Intervallo 1D:
$714.74
$729.99
Intervallo di 1 settimana:
$709.00
$731.31
Portata 52W:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
719.39 | 670.62B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
152.43 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
183.09 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
111.87 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
68.60 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - TradingView
BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail
Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net
Lilly to acquire biotech developing pain drugs - statnews.com
Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal
Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers
Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? - The Motley Fool
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey
Lilly snags Peninsula non-opioid pain drug company for up to $1 billion - The Business Journals
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360
Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters
Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks
Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus
Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus
Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news
Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com
Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly to acquire privately held SiteOne - Yahoo
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics - Eli Lilly and Company
Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lilly's blood drive breaks site record - reporter.net
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - aol.com
Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks
Prurigo Nodularis Market - GlobeNewswire Inc.
Eli Lilly (LLY) Faces Lowered Market Forecast for Anti-Obesity D - GuruFocus
Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities - The Globe and Mail
Is Eli Lilly Stock A Sell After Novo Nordisk Wins An Unexpected Obesity Edge? - Investor's Business Daily
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
With short film, Eli Lilly is Seeking to transform itself as a drugmaker - PR Week
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen - Yahoo Finance
Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer’s Treatment - Insider Monkey
Eli Lilly & Co. (LLY) gives presentation highlights for 2025 ASCO - StreetInsider
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen - Yahoo Finance
ELI LILLY AND COMPANY (LLY) - MSN
Morgan Stanley Reiterates Buy Rating on Eli Lilly Stock (LLY), Citing New Copay Strategy - TipRanks
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):